|
|
DF/HCC News
BRAF/MEK: The science of targeting one oncogenic pathway In theory, it sounds straightforward: Find genetic mutations essential to the growth and survival of the cancer, identify specific inhibitors in the lab, and validate them in human studies
The future of BRAF inhibitors It is daunting for even the most dedicated of scholars to track the alphabet soup of promising molecular targets and pathways
Forty-one new members join DF/HCC Forty-one individuals have recently joined DF/HCC
Epidemiology pinpoints cancer risk factors and survival strategies Some cancers are on the rise, but the overall U.S
Phase II trial aims to extend ablation to larger liver tumors Hepatocellular (HCC) cancer generally has a poor prognosis and, in contrast to other cancers in the United States, mortality is increasing
CURE program in eighth year of success This year, 50 students participated in the CURE program – a training opportunity that offers hands-on research experience to high school and college students with the goal of encouraging careers in cancer research
Health Communication Core The Health Communication Core (HCC) provides evidence-based communication expertise to investigators working in the areas of cancer prevention, control, treatment, and survivorship
Displaying results 43 to 49 out of 184
|
